Aridis Pharmaceuticals Stock Performance
Aridis Pharmaceuticals stock opened at $1.86 on Tuesday. The stock’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.55. The firm has a market capitalization of $32.93 million, a PE ratio of -0.50 and a beta of 1.13. Aridis Pharmaceuticals has a one year low of $0.88 and a one year high of $4.34.
Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) last announced its earnings results on Tuesday, August 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.39). On average, analysts forecast that Aridis Pharmaceuticals will post -0.34 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aridis Pharmaceuticals
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
- Get a free copy of the StockNews.com research report on Aridis Pharmaceuticals (ARDS)
- Institutional Support For TJX Companies May Cap Gains
- Is Sanofi A Buy, Despite Recent Stumbles?
- If You Hate Speed Cameras, Then You’ll Like Verra Mobility Stock
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ’s Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.